Onsdag 30 Oktober | 09:25:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-05-02 07:45:00

Normalising sales pattern in MedTech

  • Net revenue increased by 4 per cent to EUR 91.3m (88.1) with organic growth of 1 per cent
  • Adjusted EBITA EUR 24.1m (26.1) corresponding to a margin of 26.3 per cent (29.6)
  • Operating profit (EBIT) of EUR 13.4m (18.5)
  • Profit of EUR 3.7m (5.5) and earnings per share before and after dilution EUR 0.01 (0.01)
  • Cash flow from operating activities of EUR 11.2m (1.1)

“The animal health market continues to show solid growth in the first quarter. Vimian’s organic growth of 1 per cent and adjusted EBITA margin of 26.3 (29.6) per cent reflects our decision to reduce the size of the annual ordering program in US MedTech, to better phase sales across the year with no impact on the full year. Specialty Pharma and Veterinary Services continue to deliver strong organic growth of 11 and 15 per cent respectively”, says Patrik Eriksson, CEO of Vimian Group and continues:

“During the first quarter, we completed a successful rights issue, announced new financial targets and our intention to change listing venue to Nasdaq Stockholm main market. With these building blocks in place, we are well equipped to create significant shareholder value over the years to come.“

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50047232

To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q1-report-2024

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.